SCHEMBL19768992

SCHEMBL19768992

CC(C)c1cccc(F)c1C=NO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRB2 P47870 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 2/20 0.41
FAAH O00519 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
GABRB1 P18505 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2C P28335 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
HTR2B P41595 1/20 0.41
GABRA2 P47869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19779453 1.00 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2HPGD
SCHEMBL19779831 0.81 SMN1; SMN2 (0.36) LMNATSHRSMN1; SMN2ALDH1A1PKM
SCHEMBL4398099 0.80 POLB (0.44) HPGDLMNACYP1A2SMN1; SMN2GFER
SCHEMBL20148150 0.80 POLB (0.44) HPGDLMNACYP1A2SMN1; SMN2GFER
SCHEMBL4398103 0.80 POLB (0.44) HPGDLMNACYP1A2SMN1; SMN2GFER
SCHEMBL19768995 0.79 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRB2HPGD
SCHEMBL19779386 0.79 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRB2HPGD
SCHEMBL20621409 0.79 CYP1A2 (0.41) GABRA1GABRG2GABRB3GABRB2HPGD
SCHEMBL19768993 0.79 CYP1A2 (0.41) GABRA1GABRG2GABRB3GABRB2HPGD
Hydrochloric Acid SCHEMBL28114698 0.78 POLB (0.43) HPGDLMNACYP1A2SMN1; SMN2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 US disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 GABRA1 322/4885GABRG2 274/4885GABRB3 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.